In the rapidly evolving pharmaceutical landscape, insights have become the lifeblood of strategic decision-making. Every conversation with a healthcare professional (HCP), every question raised at a medical congress, every inquiry fielded by medical information teams—these moments contain valuable intelligence that can shape product strategies, inform clinical development, and enhance patient outcomes.
Yet despite the critical importance of insights, many pharmaceutical companies continue to manage them using tools never designed for this purpose: Customer Relationship Management (CRM) systems with a few extra fields tacked on as an afterthought.
This approach is no longer sustainable. As the volume, velocity, and variety of insights data explode, Medical Affairs teams are drowning in information while starving for actionable intelligence. The gap between what insights could deliver and what legacy systems actually provide has never been wider.
This is why 2026 marks a turning point: the pharmaceutical industry is rapidly transitioning from CRM-based insights management to dedicated, end-to-end Insights Management Platforms (IMPs) designed specifically for the unique demands of life sciences.
In this comprehensive guide, we’ll explore why this shift is happening, what defines a true end-to-end insights solution, and how to evaluate platforms that can transform your insights from scattered data points into strategic competitive advantages.
Why Traditional CRM Systems Fall Short for Pharma Insights Management
The “Few Extra Fields in CRM” Problem
Most pharmaceutical companies began capturing insights the same way: by adding custom fields to their existing CRM systems. At first glance, this seemed logical—field teams were already using the CRM to log HCP interactions, so why not capture insights there too?
The problem is that CRMs were built to manage relationships, not intelligence. They excel at tracking who your teams are meeting, how often, and what products were discussed. But when it comes to capturing the nuanced, unstructured, strategically vital insights that emerge from those conversations, CRMs fall dramatically short.
The limitations are numerous:
- Limited capture capabilities: Free-text fields can’t guide users toward capturing high-quality, actionable insights. There’s no real-time prompting with Key Information Questions (KIQs), no structured methodology to ensure consistency across thousands of field interactions.
- No contextual intelligence: A CRM doesn’t understand the meaning behind an insight. It can’t automatically detect that a comment about a drug’s side effect profile is critically different from a general efficacy observation. Without AI-powered analysis, every insight looks the same—just another row in a database.
- Poor user experience: Medical Science Liaisons (MSLs) and Medical Affairs professionals didn’t sign up to be data entry clerks. When insights capture feels like administrative burden rather than strategic contribution, quality suffers and adoption plummets.
Data Silos: The Hidden Cost of Fragmented Systems
Perhaps the most damaging limitation of CRM-based insights management is the proliferation of data silos. In the modern pharmaceutical enterprise, insights originate from dozens of sources:
- Field teams conducting one-on-one HCP engagements
- Congress and conference teams capturing reactions to scientific presentations
- Medical information centers fielding questions about products
- Advisory boards providing structured strategic feedback
- Social media monitoring revealing real-world patient and provider sentiment
- Publications and literature review tracking emerging scientific trends
When each of these channels uses different systems—or worse, different Excel spreadsheets—the result is a fragmented view of the landscape. Medical Affairs can’t see the full picture. Trends that span multiple data sources go undetected. Strategic opportunities slip through the cracks.
A VP of Medical Affairs at a leading global pharmaceutical company recently described the problem this way: “We had insights everywhere and insights nowhere. Five different teams were hearing similar feedback from the market, but none of us knew it because we were all working in our own silos.”
The AI Gap: Manual Analysis in an Automated World
Even when insights are successfully captured in a CRM, the next challenge emerges: analysis. How do you identify trends across thousands of interactions? How do you spot early signals of safety concerns or competitive threats? How do you translate raw feedback into strategic recommendations?
In most organizations, this analysis happens manually—if it happens at all. Analysts spend weeks exporting data, cleaning it, categorizing it, and building PowerPoint presentations. By the time insights reach decision-makers, they’re often stale. The market has moved on.
Modern AI-powered platforms can perform in minutes what takes human analysts weeks:
- Auto-tagging to categorize insights by therapeutic area, topic, sentiment, and priority
- Sentiment analysis to gauge HCP attitudes and concerns
- Trend extraction to surface patterns across thousands of interactions
- Insight triangulation to connect dots across disparate data sources
CRM systems, designed in an era before AI, simply weren’t architected to support these capabilities. Adding them as bolt-ons is possible, but the results are clunky, expensive, and rarely deliver the seamless intelligence modern Medical Affairs teams require.
Compliance Blind Spots in Generic Tools
Finally, there’s the compliance dimension. Pharmaceutical insights management isn’t just about collecting information—it’s about doing so in a manner that meets rigorous regulatory and privacy requirements.
Generic CRM systems offer basic permission controls, but they lack the specialized compliance features pharma demands:
- Sensitive word flagging to catch potential adverse events or off-label discussions before they create liability
- Insight review workflows to ensure appropriate oversight before insights are escalated
- Functional firewalls to maintain appropriate separation between Medical and Commercial teams
- Audit trails comprehensive enough to satisfy regulatory inspections
- Zero-risk architecture designed from the ground up with pharma compliance requirements in mind
When compliance becomes an afterthought, the risks are substantial—not just regulatory penalties, but reputational damage and patient safety concerns.
What Is an End-to-End Insights Management Platform?
Definition and Core Capabilities
An end-to-end Insights Management Platform is a specialized software solution designed to manage every stage of the insights lifecycle—from the moment an insight is captured in the field to the moment it drives strategic action within the organization.
Unlike CRM add-ons or point solutions that handle only one piece of the puzzle, a true end-to-end platform orchestrates the complete workflow:
- Capture: Guiding field teams, congress attendees, and other stakeholders to record high-quality insights with proper context and structure
- Ingest: Pulling in data from all channels—CRM, email, advisory board reports, social listening tools, and more
- Tag & Label: Automatically categorizing insights using AI-powered classification
- Prioritize: Identifying which insights require immediate attention based on strategic importance, safety signals, or competitive intelligence
- Escalate: Routing critical insights to the right stakeholders with appropriate workflows and approvals
- Analyze: Applying advanced analytics, sentiment analysis, and trend detection to uncover patterns and opportunities
- Report: Generating executive-ready dashboards and reports that translate insights into strategic narratives
- Share & Communicate: Distributing insights across the organization in a compliant, controlled manner
- Action: Linking insights to strategic initiatives and tracking implementation to close the loop
This comprehensive approach ensures that insights don’t just get captured—they get used. They inform decisions, shape strategies, and drive measurable business outcomes.
How It Differs from Traditional CRM Modules
The distinction between a CRM with insights fields and a dedicated Insights Management Platform is fundamental:
| Dimension | CRM with Insights Module | Dedicated Insights Platform |
| Primary Purpose | Manage customer relationships | Manage strategic intelligence |
| Data Model | Contact-centric | Insight-centric |
| AI Capabilities | Basic or bolt-on | Native, deeply integrated |
| Cross-functional | Limited | Designed for Medical, Commercial, R&D collaboration |
| Compliance | Generic controls | Pharma-specific, zero-risk architecture |
| Analytics | Basic reporting | Advanced trend detection, sentiment analysis, triangulation |
| User Experience | Data entry focus | Intelligence contribution focus |
| Integration | Siloed | Single source of truth across all channels |
Perhaps most importantly, a dedicated platform treats insights as the strategic asset they are—not as an afterthought squeezed into a system designed for a completely different purpose.
The Single Source of Truth: Why It Matters
One of the most transformative aspects of an end-to-end insights platform is its role as a single source of truth. Rather than having insights scattered across CRMs, spreadsheets, email threads, and shared drives, everything flows into one unified system.
This consolidation delivers immediate benefits:
- Comprehensive analysis: When all insights are in one place, you can truly understand what the market is telling you
- Reduced duplication: No more multiple teams asking the same HCPs the same questions
- Organizational alignment: When everyone accesses the same insights dashboard, strategic conversations become more focused and productive
- Historical intelligence: Years of insights remain accessible, revealing long-term trends and patterns
The impact of this unified approach cannot be overstated. Medical Affairs leaders consistently report that moving from fragmented systems to a single insights platform fundamentally changes how their organizations operate—from reactive to proactive, from anecdotal to evidence-based, from siloed to connected.
Real-World Impact: Insights at Scale
To understand the true potential of modern insights platforms, consider the scale at which they now operate. Leading pharmaceutical companies are managing insights at levels that would have been impossible just a few years ago:
- Over 400,000 insights captured, analyzed, and actioned
- 4,500+ teams using insights platforms daily across diverse roles and functions
- 80+ countries deploying unified insights infrastructure
- Multiple languages supported to enable truly global insights strategies
This isn’t theoretical—these are real numbers from platforms like X-Fly, the world’s most comprehensive Insights Management Platform designed specifically for pharma.
When insights management operates at this scale, the question shifts from “Can we capture insights?” to “What strategic advantage can we create from the intelligence we’re gathering?”
The 5 Non-Negotiable Features of Modern Pharma Insights Platforms
As pharmaceutical companies evaluate their options for insights management, certain capabilities have emerged as non-negotiable. These five features separate truly transformational platforms from glorified databases:
1. AI-Powered Intelligence: From Data to Understanding
Artificial intelligence isn’t a “nice to have” feature—it’s the foundational technology that makes modern insights management possible. Without AI, you’re simply creating a larger haystack in which to search for needles.
The best insights platforms integrate AI seamlessly throughout the entire workflow (think of it as “butter spread evenly on toast,” rather than AI features tacked on in isolation):
Auto-tagging and classification: Instead of requiring field teams to manually select from hundreds of tags and categories, AI automatically classifies insights by therapeutic area, topic, product, sentiment, priority, and more. This ensures consistency, saves time, and dramatically improves data quality.
Real-time Key Information Questions (KIQs): AI can prompt field teams with relevant questions based on context—the HCP they’re meeting, recent market trends, or strategic priorities. This transforms insights capture from passive data entry to active intelligence gathering.
Sentiment analysis: Understanding not just what HCPs are saying, but how they feel about it. Is there enthusiasm about a new indication? Concern about a competitor’s messaging? Frustration with access barriers? Sentiment analysis makes these nuances visible and quantifiable.
Trend extraction: Across thousands of insights, AI identifies emerging patterns—upticks in specific questions, shifts in prescribing attitudes, early signals of safety concerns, or opportunities for medical education.
Insight triangulation: Perhaps most powerfully, AI can connect insights across different sources and channels. It might notice that concerns raised at a medical congress correlate with questions coming into the medical information center, suggesting a broader market trend that requires strategic response.
AI-led report generation: Instead of analysts spending days building presentations, AI can generate executive-ready summaries, highlighting the most critical insights, supporting evidence, and recommended actions.
Conversational data interrogation: The most advanced platforms now offer agentic AI capabilities—allowing stakeholders to ask questions of the insights database in natural language and receive intelligent, contextual answers. “What are cardiologists saying about our Phase 3 data?” “How has sentiment about our competitor changed in the last quarter?” These questions get answered in seconds, not days.
2. Cross-Functional Collaboration Tools: Breaking Down Silos
Insights don’t respect organizational boundaries. A concern raised by an MSL in the field may be relevant to Medical Communications, Clinical Development, Commercial Strategy, and Patient Advocacy. Yet in many organizations, these functions operate in silos, duplicating efforts and missing opportunities.
Modern insights platforms are designed to be inherently cross-functional:
- Role-based dashboards: Each stakeholder sees the insights most relevant to their function, presented in the format most useful for their decisions
- Compliant sharing: Insights can be shared across functional boundaries with appropriate controls and firewalls (e.g., Medical insights shared with Commercial teams with proper protections)
- Collaboration workflows: Insights can be flagged for input from multiple stakeholders, creating digital “working groups” around specific strategic questions
- Connected stakeholders: Everyone involved in the insights process—from field teams capturing data to executives making strategic decisions—uses the same platform, creating organizational alignment
This connected approach ensures that insights don’t get trapped in functional silos. They flow to where they can create the most value.
3. Compliance-First Architecture: The Zero-Risk Objective
In pharmaceutical insights management, compliance isn’t optional—it’s existential. A single compliance failure can result in regulatory penalties, consent decrees, or worse.
This is why the best insights platforms are built from the ground up with a “zero-risk objective”—every design decision informed by regulatory requirements and industry best practices:
Sensitive word flagging: Automatic detection of potential adverse events, off-label references, or other red-flag terms that require immediate review and proper handling.
Insight review workflows: Configurable approval processes ensuring insights are reviewed by appropriate personnel before being escalated or shared more broadly.
User permissions and functional firewalls: Granular controls over who can see, edit, share, and action insights, with particular attention to maintaining appropriate separation between Medical and Commercial activities.
Data privacy and protection: Enterprise-grade security protocols, encryption, access controls, and audit trails that meet or exceed GDPR, HIPAA, and other global data protection standards.
Regulatory reporting: The ability to generate compliant reports for regulatory submissions, demonstrating how insights informed safety monitoring, risk management, or other regulated activities.
Audit trails: Comprehensive tracking of every action taken on every insight—who captured it, who viewed it, who edited it, who escalated it, and who acted on it.
When compliance is baked into the architecture rather than bolted on as an afterthought, organizations can move faster with confidence rather than being paralyzed by risk aversion.
4. Scalability and Configurability: From Pilot to Global Enterprise
Pharmaceutical organizations are complex—spanning geographies, therapeutic areas, products, and organizational structures. An insights platform that works for one team in one country may break down when scaled globally.
The best platforms offer both scalability (the ability to grow) and configurability (the ability to adapt):
Start small, scale fast: Begin with a single pilot team, demonstrate quick wins, then expand to additional teams, regions, or therapeutic areas without requiring a complete reimplementation.
Multi-dimensional configuration: Support for global/regional/country hierarchies, multiple therapeutic areas, diverse team structures, different languages, and varied workflows—all within a single platform instance.
Workflow flexibility: The insights process at a small biotech may differ dramatically from a Top 10 pharma. Configurable workflows ensure the platform adapts to your process, not the other way around.
Modular architecture: Rather than forcing you to adopt every feature, the best platforms allow you to pick and choose the components most valuable for your specific needs—creating a solution perfectly tailored to your organization.
This flexibility is crucial because insights management isn’t one-size-fits-all. Each organization has unique strategic priorities, regulatory environments, and cultural contexts that must be respected.
5. Seamless Tech Stack Integration: Making Insights Part of the Workflow
An insights platform doesn’t exist in isolation—it must integrate seamlessly with your broader technology ecosystem. This includes:
Upstream integration: Pulling data from CRMs, email systems, congress management tools, advisory board platforms, social listening solutions, and other sources where insights originate.
Midstream integration: Connecting with analytics platforms, business intelligence tools, and data warehouses to enable advanced analysis and reporting.
Downstream integration: Pushing insights and intelligence into CRMs, project management systems, and strategic planning tools where they inform action.
The goal is to make insights management feel like a natural part of existing workflows rather than yet another system requiring separate logins, redundant data entry, and manual synchronization.
Pain-free integration across the entire tech stack ensures high adoption rates, better data quality, and ultimately more valuable insights.
Case Study: How a Top 10 Pharma Transformed Medical Affairs with X-Fly
Theory is valuable, but nothing illustrates the power of end-to-end insights management better than a real-world transformation story.
A Vice President of Medical Affairs at a Top 10 pharmaceutical company recently described their experience implementing X-Fly, the world’s most comprehensive Insights Management Platform:
“X-Fly has completely transformed our entire medical excellence program from the ground up. From training on the right way to collect insights, analyzing trends from recent conversations, reporting it up the chain to senior management, and actioning relevant ones—I can’t recommend it more.”
The Challenge
Before implementing X-Fly, this organization faced challenges common across the industry:
- Inconsistent insights capture: Different teams in different countries were using different approaches, making aggregated analysis nearly impossible
- Slow cycle times: It took weeks or months for insights captured in the field to make their way to decision-makers
- Limited visibility: Senior leadership had no real-time view into what the market was telling them
- Missed strategic opportunities: Valuable insights were getting lost in email threads and Excel spreadsheets
The Transformation
The implementation of X-Fly touched every aspect of their insights process:
1. Training and Standardization
X-Fly provided a common framework and methodology for insights capture. Field teams received training not just on the platform, but on the fundamentals of gathering high-quality insights—what questions to ask, how to capture context, and why insights matter strategically.
2. Real-Time Trend Analysis
Instead of waiting for quarterly reports, leadership gained real-time visibility into emerging trends. AI-powered analytics surfaced patterns across therapeutic areas, geographies, and stakeholder groups—enabling proactive rather than reactive strategic responses.
3. Executive Reporting
Automated, AI-led report generation transformed how insights were communicated to senior management. Instead of analysts spending weeks building decks, executives received timely, executive-ready summaries highlighting the most critical intelligence and recommended actions.
4. Action Tracking and Accountability
Perhaps most importantly, X-Fly enabled the organization to close the loop on insights—linking them to specific strategic initiatives and tracking implementation. Insights no longer disappeared into a black box; their impact became visible and measurable.
Measurable Outcomes
While specific metrics are confidential, the organization reported significant improvements across multiple dimensions:
- Faster decision-making: Cycle time from insight capture to strategic action reduced dramatically
- Higher data quality: Standardized processes and AI-powered guidance improved the quality and actionability of insights
- Improved collaboration: Cross-functional teams gained a shared view of market intelligence, reducing silos and duplicated effort
- ROI demonstration: For the first time, Medical Affairs could quantify the value of insights in driving strategic outcomes
This transformation from fragmented, reactive insights management to a coordinated, strategic intelligence function represents the promise of end-to-end platforms—not just incremental improvement, but fundamental change in how organizations operate.
How to Evaluate Insights Management Platforms: A Buyer’s Checklist
If you’re responsible for selecting an insights management solution for your organization, the options can seem overwhelming. Here’s a practical checklist to guide your evaluation:
Questions to Ask Vendors
Regarding platform capabilities:
- Can you demonstrate the complete workflow from capture to action?
- How is AI integrated throughout the platform? (Look for native integration, not bolt-ons)
- What compliance controls are built into the system?
- How does the platform handle cross-functional insights sharing?
- Can you show examples of dashboards and reports generated by the system?
Regarding implementation and scalability:
- What is the typical implementation timeline? (Be wary of anything over 3-6 months for initial deployment)
- Can we start with a pilot and scale incrementally?
- How configurable is the platform to our specific workflows and organizational structure?
- What languages and geographies do you support?
Regarding integration:
- What integrations are available out-of-the-box?
- How do you handle upstream data ingestion from our CRM and other systems?
- Can insights flow downstream into our strategic planning and project management tools?
- What is your API strategy for custom integrations?
Regarding support and partnership:
- What onboarding and training do you provide?
- How is ongoing support structured? (Help desk, dedicated account management, etc.)
- What resources exist for user engagement and adoption?
- Can you share references from similar organizations?
Regarding vendor viability:
- What is your company’s backing and long-term stability?
- How many pharmaceutical organizations are currently using your platform?
- What is your product roadmap?
- How do you incorporate customer feedback into development priorities?
Must-Have vs. Nice-to-Have Features
As you evaluate options, distinguish between essential capabilities and features that are merely desirable:
Must-Have Features:
- End-to-end workflow management (capture → action)
- AI-powered auto-tagging and analysis
- Compliance controls (sensitive word flagging, review workflows, audit trails)
- Cross-functional collaboration with appropriate firewalls
- Scalability from pilot to global deployment
- CRM and tech stack integration
- Mobile accessibility for field teams
- Multi-language support
- Role-based permissions and dashboards
Nice-to-Have Features:
- Conversational AI/agentic interrogation
- Advanced predictive analytics
- Social media listening integration
- Integration with specific congress/event management platforms
- Highly customized reporting templates
- White-label options
Focus your evaluation on vendors who excel at the must-haves. Nice-to-haves can be considered as differentiators among otherwise comparable options.
Implementation Timeline and Support Considerations
One often-overlooked dimension of platform evaluation is implementation complexity and ongoing support requirements.
Red flags to watch for:
- Implementations that require 12+ months before value realization
- Heavy dependence on third-party consultants or system integrators
- Limited training and onboarding resources
- Support that’s only available via ticketing systems with slow response times
- Lack of dedicated customer success resources
Green flags to look for:
- Rapid implementation (some platforms like X-Fly can be implemented in as little as two weeks for initial pilots)
- Comprehensive onboarding and training programs
- Dedicated support desk with subject matter expertise in pharma insights
- Customer success managers who proactively drive adoption and value realization
- User community and ongoing engagement resources
- Regular training updates as new features are released
Remember: The platform itself is only part of the equation. The people, processes, and support infrastructure around it determine whether your implementation succeeds or stalls.
The Future of Insights Management in Pharma
As we look ahead, several trends are shaping the next generation of pharmaceutical insights management:
The Rise of Conversational and Agentic AI
The future of insights interrogation is conversational. Rather than navigating through complex menus, filters, and dashboards, stakeholders will simply ask questions in natural language:
- “What are the top concerns oncologists have raised about our drug in Q4?”
- “How does sentiment about our competitor compare across European markets?”
- “Show me insights related to patient access barriers in the last six months.”
These conversational AI agents won’t just retrieve data—they’ll synthesize insights, identify patterns, and even suggest strategic responses. The insights platform becomes less of a database and more of an intelligent strategic advisor.
Modular, Composable Platforms: Build Your Perfect Solution
Just as the tech industry has embraced composable architectures, insights platforms are moving toward greater modularity. Organizations will increasingly have the ability to:
- Select specific modules that address their most pressing needs
- Integrate best-of-breed point solutions within a unified framework
- Customize workflows without extensive development work
- Adapt quickly as strategic priorities evolve
This modular approach allows organizations to start small, demonstrate value quickly, and expand incrementally—rather than betting everything on massive, multi-year platform implementations.
Proactive Insights: From Reactive Analysis to Predictive Intelligence
Today’s insights platforms are largely reactive—they help you understand what’s happening now. Tomorrow’s platforms will be increasingly predictive:
- Identifying early signals of market shifts before they become obvious
- Forecasting how HCP sentiment might evolve based on emerging data
- Recommending proactive actions based on patterns learned from historical insights
- Alerting stakeholders to anomalies or unexpected trends requiring immediate attention
This shift from reactive to predictive intelligence represents a fundamental upgrade in the strategic value insights can deliver.
Regulatory Evolution and Compliance Requirements
As regulatory agencies increasingly focus on how pharmaceutical companies use real-world data and insights to inform safety monitoring, risk management, and strategic decisions, compliance requirements will continue to evolve.
Forward-thinking insights platforms are already anticipating these changes:
- Enhanced audit trails that document not just what insights were captured, but how they informed decisions
- Tighter integration with pharmacovigilance systems to ensure potential safety signals are handled appropriately
- Capabilities to demonstrate to regulators that insights processes are robust, consistent, and compliant
- Tools to support regulatory submissions that leverage real-world insights
Organizations that invest in compliance-first platforms now will be better positioned to adapt as requirements evolve.
The Integration of Patient Insights
While much of pharmaceutical insights management has historically focused on HCP intelligence, there’s growing recognition of the strategic value of direct patient insights. Future platforms will increasingly integrate:
- Patient support program data
- Patient advocacy group feedback
- Social media sentiment from patient communities
- Real-world evidence from wearables and digital health tools
This more holistic view—combining HCP, payer, and patient perspectives—will enable pharmaceutical companies to make more informed, patient-centric strategic decisions.
Conclusion: The Strategic Imperative
The pharmaceutical industry stands at an inflection point. The volume of insights available to organizations has never been greater, yet many companies struggle to translate this data into strategic advantage. The gap between insights potential and insights reality represents both a challenge and an opportunity.
Traditional CRM systems, designed for relationship management rather than intelligence gathering, are increasingly unable to meet the demands of modern Medical Affairs organizations. They create silos, slow decision-making, lack AI-powered intelligence, and introduce compliance risks.
End-to-end Insights Management Platforms represent the next evolution—purpose-built solutions that manage the complete insights lifecycle, from capture to action. These platforms don’t just store insights; they transform them into strategic intelligence that drives competitive advantage.
As you evaluate your organization’s approach to insights management, ask yourself:
- Are we capturing insights consistently across all channels and geographies?
- Can we analyze trends and patterns in real-time, or are we constantly looking in the rearview mirror?
- Do our insights flow seamlessly to decision-makers, or do they get lost in organizational silos?
- Are we confident in our compliance posture, or are we worried about potential gaps?
- Can we demonstrate the ROI and strategic impact of our insights activities?
If you answered “no” to any of these questions, it may be time to explore dedicated insights management platforms.
The organizations that win in the next decade won’t be those with the most data—they’ll be those who can most effectively transform insights into action. The right platform makes all the difference.
Ready to transform your insights process?
X-Fly is the world’s most comprehensive Insights Management Platform, trusted by over 4,500 teams in 80+ countries to manage over 400,000 insights.
With complete end-to-end capabilities, seamlessly integrated AI, compliance-first architecture, and proven results at Top 10 pharma companies, X-Fly can transform your Medical Affairs insights from scattered data into strategic competitive advantage.
Book a demo and see how X-Fly can revolutionize your insights management.
Download the brochure to learn more about X-Fly’s capabilities and customer success stories.
About VML Health Platforms
VML Health Platforms is part of VML, the world’s largest and most awarded creative agency with 30,000 employees worldwide. With 10,000 technologists across 30 countries and deep healthcare expertise, VML combines creative excellence with technological innovation to deliver enterprise solutions trusted by the world’s leading pharmaceutical companies.
X-Fly is backed by the stability and resources of WPP (LSE: WPP; NYSE: WPP), ensuring long-term support and continuous innovation.